Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (2666)	1/14/2010 9:29:32 AM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

SNSS is up 19.72% in premarket trading.<g> bigcharts.marketwatch.com It announced the publication of studies with its lead drug candidate, voreloxin, in the journal Cancer Chemotherapy and Pharmacology. The results demonstrate voreloxin's potent cytotoxic activity in human acute leukemia cell lines and in an in vivo model when used alone, and enhanced or synergistic activity when used in combination with cytarabine. SNSS is completing a PII of voreloxin as a single-agent or in combination with cytarabine in AML,(which it had started in May 2008), and expects to begin a PIII later in 2010. Voreloxin, alone and in combination with cytarabine, was evaluated in 3 human acute leukemia cell lines: HL-60 (acute promyelocytic leukemia), MV4-11 (AML with a FLT3 mutation) and CCRF-CEM (acute lymphoblastic leukemia). The drug was active in all the leukemia cell lines, including the AML cell line, which is relatively resistant to cytarabine in vitro. The stock already had a previous spike in early December.(Dec8 to Dec 11 <g>) That was when voreloxing was granted orphan drug status by the FDA in AML. bigcharts.marketwatch.com Bernard